Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
 

Ministerstvo xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. xxxxx 2023 xxxx xxxxxxxxx xxxxxxxxxx UNESCO xxxxxxxx xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx zakázaných xxxxx x xxxxx xxxxxxx xxx xxx 2024 - Xxxxxxxxxxx standard Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu.

S xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx o xxxxxxx xxxx Xxxxxxx X Xxxxxx republikou.

Nové xxxxx Xxxxxxx I xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx republiku xxxxxxxxx x xxxxxxxx xxx 18. xxxxxx 2024 x xxxxxxxxx Xxxxxxx X xxx xxx 2023, xxxxxxx xx 1. xxxxx 2023, xxxxx vstoupila x xxxxxxxx xxx Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx vyhlášena xxx č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X xxx xxx 2024 x její xxxxxxx do českého xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x z. XXXx. Xxxxxx, Xx.X., LL.M., x. x.

xxxxxx xxxxxxx xxxxx xxxxxx a xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Xxxxxxx xxxxxxxxxxx xxxxxxx do xxxxxxx xxxxxx

Xxxx

Xxxxxx zakázaných xxxxx x xxxxx xxxxxxx je xxxxxxx Xxxxxxxxxxx standard v xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx xx každoročně xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx procesu xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx agenturou (XXXX). Xxxxxx xx xxxxxx od 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxx xxxxxxxxx XXXX x xxxx publikován x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx znění x xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx xxxxx používané x tomto Seznamu xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Xxx soutěži

Pokud XXXX xxx xxxx xxxxx xxxxxxxxxxx jiné xxxxxx, je období Xxx xxxxxxx x xxxxxx obdobím xxxxxxxxxxx xxxxx xxxx půlnocí (xx 23:59 hodin) x den xxxxxxxxxxxxx Xxxxxxx, xxxxx se xx Xxxxxxxxx zúčastnit, xx xx konce Xxxxxxx x xxxxxxx xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, že xxxx xxxxx xxxx xxxxxx xx zakázána Při xxxxxxx x Xxxx xxxxxx, xxx xx xxxxxxxxxx v Xxxxxx.

Xxxxxxxxxx x Nespecifické

Podle xxxxxx 4.2.2 Xxxxxxxxx antidopingového Xxxxxx „pro xxxxx xxxxxxxx článku 10 xxxxx všechny Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x výjimkou xxxx xxxxxxxxxx x Xxxxxxx xxxxxxxxxx látek x xxxxx dopingu. Xxxxx Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx xxxxxxx, pokud xxxx v Xxxxxxx xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx x xxxxxx „Xxxxxxxxxx látky x Xxxxxxxxxx metody xxxxxxx x xxxxxx 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx považovány xx xxxx důležité xxxx méně nebezpečné xxx xxxx xxxxxxxxx xxxxx nebo xxxxxx. Xxx spíše x xxxxx x xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx použil x xxxxxx účelu xxx ke xxxxxxxx xxxxxxxxxxx xxxxxx.“

Xxxxxxxx látky

Podle xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx xxxx xxxx xxxxxx označeny x xxxxxx xxxxxx xxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxx rámec sportu. Xxxx Xxxxxxxx xxxxx xxxx označovány tyto xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 NESCHVÁLENÉ XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxx zakázané xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky.

Jakákoliv xxxxxxxxxxxxxx látka, xx xxxxxx xx xxxxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxx Seznamu x xxxxx není v xxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx zdravotnickým xxxxxxxxxx orgánem pro xxxxxxx použití x xxxx (xxxx. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx vývoji nebo xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx xxxxxxx), xx zakázána xxxxx.

Xxxx xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxx (xxxx. Reldesemtiv x Xxxxxxxxxx).

X1 XXXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxxxx látky.

Anabolické xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)

Xxx xxxxxxxxx podání, xxxx xxxx včetně:

•	1-androstenediol (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on)		•	mesterolon
•	4-androstenediol (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on)
•	4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on)		•	metenolon
•	5-androstenedion (xxxxxxx-5-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		&xxxx;•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-hydroxy-17α-metylestra-4,9-dien-3-on)
•	17ɑ-methylepithiostanol (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on)
•	19-norandrostenediol (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-hydroxy-17ɑ-methylestra-4,9,11-trien-3-on)
•	Androst-4-en-3,11,17-trion(11-ketoandrostenedion, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxx (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (androst-4-en-3,17-dion)		•	norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxx
•	xxxxxxxxx		&xxxx;•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (dehydroepiandrosteron, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)		&xxxx;•	xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-methyl-5ɑ-androst-2-en-17ß-ol x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- ol)		•	quinbolon
•	dimetandrolon (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on)		•	testosteron
•	epi-dihydrotestosteron (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-norpregna-4-en-17α-ol)		•	trenbolon (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

S1.2. XXXXXXX XXXXXXXXXX XXXXX

Xxxx xxxx xxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], zeranol x xxxxxxxxxx.

X2 XXXXXXXXX HORMONY, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx látky.

Následující látky x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky xxxx xxxxxxxx.

X2.1. XXXXXXXXXXXXX (XXX) X XXXXX OVLIVŇUJÍCÍ XXXXXXXXXXX

Xxxx xxxx včetně:

S2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. darbepoetiny (xXXX); xxxxxxxxxxxxx (XXX); sloučeniny xxxxxxxx xx XXX, [xxxx. EPO-Fc, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx a xxxxxx xxxxxxxxxx, xxxx. XXXX-530, peginesatid.

S2.1.2 Xxxxxxxxx xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), např. xxxxxx; xxxxxxxxxxx (GSK1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.

X2.1.4 Inhibitory xxxxxxxxxxx xxxxxxxxxxxxxxxx růstového xxxxxxx xxxx (TGF-β), xxxx. xxxxxxxxxxxx; sotatercept.

S2.1.5 Agonisté xxxxxxxxx xxxxxxxxx receptoru, xxxx. asialo XXX; xxxxxxxxxxxxx XXX (XXXX).

X2.2. XXXXXXXXX XXXXXXX A XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x mužů, xxxx xxxx včetně:

• choriový xxxxxxxxxxxx (XX),

• xxxxxxxxxxxx xxxxxx (XX),

• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (GnRH, xxxxxxxxxxx) x xxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, deslorelin, goserelin, xxxxxxxxx, leuprorelin, xxxxxxxxx x xxxxxxxxxxx),

&xxxx;• xxxxxxxxxx x xxxx xxxxxxxxxxx xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.

X2.2.3 Růstový xxxxxx (XX), xxxx analogy x xxxxxxxxx, mimo xxxx xxxxxx:

• xxxxxxx xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, somapacitan x xxxxxxxxxx,

• xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. AOD-9604 x xXX 176–191.

X2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, xxxx jiné xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx hormon (GHRH) x jeho xxxxxxx, xxxx. CJC-1293, CJC-1295, xxxxxxxxxx a tesamorelin,

• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) x xxxxxx xxxxxxxx [např. anamorelin, xxxxxxxxxxxx, ibutamoren (MK-677), xxxxxxxxxx, lenomorelin (ghrelin), xxxxxxxxxxx x xxxxxxxxxxx],

• xxxxxxx xxxxxxxxxx GH (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, XXXX-5 a XXXX-6].

X2.3. XXXXXXX XXXXXXX X MODULÁTORY XXXXXXXXX XXXXXXX

Xxxx xxxx xxxxxx:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (XXX)

• růstový xxxxxx 1 podobný xxxxxxxx (IGF-1, xxxxxxxxxx) x xxxx analogy

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• růstový faktor xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX)

• thymosin-β4 x xxxx xxxxxxxx, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX)

x xxxxx růstové faktory xxxx modulátory xxxxxxxxx xxxxxxx xxxxxxxxxxx syntézu/degradaci xxxxxxxx ve xxxxxxx, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx svalových xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx beta-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx jsou xxxxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 mikrogramů xx 24 xxxxx x xxxxxxxxxx dávkách, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;

• xxxxxxxxx formoterol: maximálně xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx salmeterol: xxxxxxxxx 200 mikrogramů xx 24 hodin;

• xxxxxxxxx vilanterol: xxxxxxxxx 25 xxxxxxxxxx xx 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx salbutamolu x xxxx x xxxxxxxx xxxxxx xxx 1000 xx/xx xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx terapeutickému xxxxxxx xxxxx a xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), pokud Sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx byl důsledkem xxxxxxxxxxxx xxxxx (inhalační) xx xx xxxx xxxxxxx xxxxxxxxx dávky.

S4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX I XXXX XXXXXX)

Xxxxxxxx látky ve xxxxxxx X4.1 x X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx xxxxxxxx xx xxxx X4.3 a X4.4 jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx modulátory jsou xxxxxxxx.

X4.1. INHIBITORY XXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on)		•	androsta-3,5-dien-7,17-dion (arimistan)
•	3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on)		•	formestan
•	4-androsten-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX LÁTKY [XXXXXXXXXXXXX A XXXXXXXXXX XXXXXXXXXX ESTROGENOVÝCH XXXXXXXXX (XXXXX)]

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX ZABRAŇUJÍCÍ XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx X		•	xxxxxxxxxx xxxxxxxxxx, xxxx.:
•	xxxxxxxxxx receptoru xxxxxxxx IIB, např.:			- xxxxx xxxxxxxxx xxxx xxxxxx xxxxxxx xxxxxxxxxx
	- xxxxxxx receptory xxxxxxxx (xxxx. ACE-031)			- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx)
•	xxxxxxxxxx xxxxx xxxxxxxxx aktivinu XXX (např. bimagrumab)			- xxxxxxxxxx xxxxxxxxxxxxxx myostatin xxxx prekurzory (např. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. METABOLICKÉ XXXXXXXXXX

X4.4.1 aktivátory AMP-aktivované xxxxxxxxxxxxx (XXXX), např. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx (PPARδ), např. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) kyselina xxxxxx (XX1516, XX501516) x xxxxxxxx Rev-erbɑ , xxxx. XX9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx insulinů

S4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX SOUTĚŽI X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxx diuretika x xxxxxxxxx xxxxx, xxxxxx xxxxx optických xxxxxxx, xxxx. d- x x-, xxxx zakázány.

Mimo xxxx xxxxxx:

•&xxxx; Xxxxxxxxx, xxxx xxxx.:

xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; kanrenon; xxxxxxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxx; spironolakton; xxxxxxxx, např. bendroflumethiazid, xxxxxxxxxxxxx a xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. konivaptan, mozavaptan, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, např.:

albumin, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;

• Xxxxxxxxxxx;

• Xxxxxxxxxx;

x xxxxx látky x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

XXXXXXX

• drospirenon; xxxxxxxx; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx inhibitorů karboanhydrázy (xxxx. dorzolamid, xxxxxxxxxxx);

• xxxxxxx xxxxxx xxxxxxxxxxx x xxxxx anestezii.

POZNÁMKA

Nález xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx prahovým xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, katinu, efedrinu, xxxxxxxxxxxxx x pseudoefedrinu xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Xxx Xxxxxxx xx xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (kromě xxxxxxxxx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx za Pozitivní xxxxxxxxxxx xxxxx (AAF), xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) xx xxxx xxxxx navíc x xx, xxxxx již xxxx udělena xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx metody x xxxx třídě xxxx Xxxxxxxxxxxx s xxxxxxxx xxxxx x X2.2, xxx jsou Xxxxxxxxxx xxxxxx.

X1. XXXXXXXXXX X XXXX A KREVNÍMI XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X1.1. Xxxxxx xxxx opětovné xxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, allogenní (xxxxxxxxx) xxxx xxxxxxxxxxx krve xxxx xxxxxxxx z xxxxxxxxx krvinek xxxxxxxxxxx xxxxxx do xxxxxxxxx xxxxxxx x xxxxxxxx xxxxxxxx xxxxxx xxxx xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx provedené x xxxxxxxxxxxxx xxxxxxxxx xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxx jiné xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (RSR13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx produkty, např. xxxxxx xxxxxxxx na xxxx hemoglobinu x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx inhalací.

M1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x krví nebo x krevními xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Xxxxxxxxx nebo Xxxxx x podvod xx účelem xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx x/xxxx úprava Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Vzorku.

M2.2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx legitimně xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo klinických xxxxxxxxxxxxxx vyšetření.

M3. XXXXXX X XXXXXXX XXXXXX

X xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx následující:

M3.1. Použití xxxxxxxxxx xxxxxxx xxxx xxxxxx analogů, xxxxx xxxxx změnit xxxxxxxx xxxxxx a/nebo xxxxxxx xxxx jakýmkoliv xxxxxxxxxxx. Xx xxxx xxxx xxxxxxxx xxxxxxxxxxx xxxxx xxxx, xxxxxxxxx genů x xxxxxxxxxxx xxxxxxx xxxx.

X3.2. Použití xxxxxxxxxx xxxx geneticky modifikovaných xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx x xxxxxxxx xxxxx xxxxxxxxx x X6.X, xxx jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx v xxxx xxxxx: kokain x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)

Všechna xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxxxxxxxxx zahrnují:

S6.A: XXXXXXXXXXXX XXXXXXXXXXX

•	xxxxxxxxx		•	xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, který není xxxxxxxx uveden x xxxxx xxxxxx, je Xxxxxxxxxxx látkou.

S6.B: SPECIFICKÁ XXXXXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin)		•	hydrafinil (xxxxxxxxx)		•	xxxxxxxxxxx x xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (parahydroxyamfetamin)		•	fenmetrazin
•	benzfetamin		•	isomethepten		•	fenprometamin
•	katin1)		•	levmetamfetamin		•	propylhexedrin
•	katinon x xxxx analogy, např. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxx3)		•	xxxxxxxxxx
•	xxxxxxxxx (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát]		•	solriamfetol
•	etamivan		•	metylfenidát		•	strychnin
•	etylfenidát		•	niketamid		•	tenamfetamin (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x další látky x xxxxxxxx chemickou xxxxxxxxxx nebo podobnými xxxxxxxxxxxx účinky

VÝJIMKY

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx v xxxxxxx xxxxxx xxxxxxx, xxxxxxx, xxxxxx xxxx xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx, fenoxazolin, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, tramazolin, xxxxxxxxxxxxx) x xxxxxxxxxxx xxxxxxxx xx Monitorovacího xxxxxxxx 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: diamorfin (heroin)

Následující xxxxxxxxx, xxxxxx jejich xxxxxxxxxx všech xxxxxxxxx xxxxxxx, xxxx. x- x x, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx a jeho xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 XXXXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny xxxxxxxx xxxxx x této xxxxx xxxx Xxxxxxxxxx xxxxx. Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x xxxxxxxxxx kanabinoidy xxxx xxxxxxxx, xxxx.

• x xxxxxx (hašiš, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx

• xxxxxxxx x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)

• xxxxxxxxxx xxxxxxxxxxx napodobující xxxxxx THC

VÝJIMKY

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx v xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, pokud xxxx xxxxxxxx jakoukoliv xxxxxxxx, xxxxxxxxx [včetně xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Jiné xxxxxxx podání (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx xx xxxxxxxxx x xxxxx výrobcem xxxxxxxxxxxx xxxxx a xxxxxxxxxxxxxx indikací.

P1 XXXX-XXXXXXXXX

XXXXXXXX X XXXXXXXX SPORTECH

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx v xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx a xxx xx xx označeno xxxxxxxx (*) x Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• xxxxxxxx/xxxxxxxxxxxx (FIS) – xxxxx xx xxxxxx, xxxxxxxxxxx skoky / U-rampa x xxxxxxxxx U-rampa / xxx xxx

• xxxxxxxxxxxx xxxxx (FIA)

• xxxxxxxx xxxxxx (CMAS)* v xxxxxxxxxxxx volného xxxxxxxx, xxxx xxxxxxxx a xxxxxxx xx terč

• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• xxxxx (WDF)

• xxxx (IGF)

• xxxxxxxx (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx také Xxxx soutěž

Mimo jiné xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx č. 2

Znění xxxxxxxxxxx smlouvy x xxxxxxxxx xxxxxx
&xxxx;

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) a xxxx x-xxxxxx: xx zakázaný xxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 5 mikrogramů x 1 xx.

²⁾ xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 150 mikrogramů x 1 ml.

³⁾ xxxxxxx x xxxxxxxxxxxx: zakázány xxx koncentraci x xxxx xxxxx než 10 mikrogramů x 1 xx.

⁴⁾ xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxx, xxxx, nebo xxxxxxxx xxxxxxxx x xxxxxxxxx anestetiky.

⁵⁾ xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx a xxxxxxxx: tyto látky xxxx xxxxxxxx do Xxxxxxxxxxxxxx programu 2024 x xxxxxx xxxxxxxxxx xx Xxxxxxxx látky.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 19/2025 Xx. xxxxx xxxxxxxxx dnem 28.1.2024.

Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx právních předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx netýká xxxxxxxxx xxxxx shora uvedeného xxxxxxxx předpisu